Benefit–risk review of different drug classes used in chronic heart failure

References

• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;128(16):e240–e327.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342–1433
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Vigen R, Maddox TM, Allen LA. Aging of the United States population: impact on heart failure. Curr Heart Fail Rep. 2012;9(4):369–374.
   PubMedGoogle Scholar
• MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102(10):1126–1131.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.
   PubMed Web of Science ®Google Scholar
• Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014;2(2):97–112.
   PubMed Web of Science ®Google Scholar
• Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975.
   PubMed Web of Science ®Google Scholar
• Pham D, Grodin JL. Dilemmas in the dosing of heart failure drugs: titrating diuretics in chronic heart failure. Card Fail Rev. 2017;3(2):108–112.
   PubMedGoogle Scholar
• Hropot M, Fowler N, Karlmark B, et al. Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int. 1985;28(3):477.
   PubMed Web of Science ®Google Scholar
• Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide investigators group. Pharmacotherapy. 1994;14(5):514–521.
   PubMed Web of Science ®Google Scholar
• Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70(2):234–239.
   PubMed Web of Science ®Google Scholar
• Parker JO. The effects of oral ibopamine in patients with mild heart failure–a double blind placebo controlled comparison to furosemide. The ibopamine study group. Int J Cardiol. 1993;40(3):221–227.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.
   Google Scholar
• Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100(12):1311–1315.
   PubMed Web of Science ®Google Scholar
• Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J. 1976;38(2):167–172.
   PubMedGoogle Scholar
• Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14(5):388–393.
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31–38.
   PubMed Web of Science ®Google Scholar
• Felker GM, O’Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2(1):56–62.
   PubMed Web of Science ®Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103(1):1–6.
   PubMed Web of Science ®Google Scholar
• Castrop H, Lorenz JN, Hansen PB, et al. Contribution of the basolateral isoform of the Na-K-2Cl- cotransporter (NKCC1/BSC2) to renin secretion. Am J Physiol Renal Physiol. 2005;289(6):F1185–F1192.
   PubMed Web of Science ®Google Scholar
• Oppermann M, Hansen PB, Castrop H, et al. Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am J Physiol Renal Physiol. 2007;293(1):F279–F287.
   PubMed Web of Science ®Google Scholar
• Braunwald E. ACE inhibitors–a cornerstone of the treatment of heart failure. N Engl J Med. 1991;325(5):351–353.
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA. 1995;273(18):1450–1456.
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987;316(23):1429–1435.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–310.
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153(8):937–942.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 1999;43(4):838–849.
   PubMed Web of Science ®Google Scholar
• Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69(5):1185–1195.
   PubMed Web of Science ®Google Scholar
• Dibner-Dunlap ME, Smith ML, Kinugawa T, et al. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol. 1996;27(2):358–364.
   PubMed Web of Science ®Google Scholar
• Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000;102(3):351–356.
   PubMed Web of Science ®Google Scholar
• Giannattasio C, Achilli F, Failla M, et al. Radial, carotid and aortic distensibility in congestive heart failure: effects of high-dose angiotensin-converting enzyme inhibitor or low-dose association with angiotensin type 1 receptor blockade. J Am Coll Cardiol. 2002;39(8):1275–1282.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999;20(2):136–139.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–691.
   PubMed Web of Science ®Google Scholar
• Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361(9372):1843–1848.
   PubMed Web of Science ®Google Scholar
• Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990;24(5):496–505.
   PubMedGoogle Scholar
• Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the cooperative north scandinavian enalapril survival study [CONSENSUS] trial). Am J Cardiol. 1992;70(4):479–487.
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987;106(3):346–354.
   PubMed Web of Science ®Google Scholar
• Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. Int J Cardiol. 2013;167(1):151–156.
   PubMed Web of Science ®Google Scholar
• Edner M, Benson L, Dahlström U, et al. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36(34):2318–2326.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–1184.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018 Jul 24;72(4):351–366.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–242.
   PubMed Web of Science ®Google Scholar
• Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16–29.
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–776.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–771.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781.
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456–2467. Epub 2008 Nov 11.
   PubMed Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102(22):2700–2706.
   PubMed Web of Science ®Google Scholar
• Vizzardi E, D’Aloia A, Giubbini R, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010 Nov 1;106(9):1292–1296.
   PubMed Web of Science ®Google Scholar
• Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558–565.
   PubMed Web of Science ®Google Scholar
• Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–791.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42.
   PubMed Web of Science ®Google Scholar
• De Denus S, O’Meara E, Desai AS, et al. Spironolactone metabolites in TOPCAT - New insights into regional variation. N Engl J Med. 2017 Apr 27;376(17):1690–1692.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation. 2003;107(12):1570–1575.
   PubMed Web of Science ®Google Scholar
• Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80(11A):15L–25L.
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94(11):2817–2825.
   PubMed Web of Science ®Google Scholar
• Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823–830.
   PubMed Web of Science ®Google Scholar
• Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558–569.
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA. 2000;283(10):1295–1302.
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215–225.
   PubMed Web of Science ®Google Scholar
• Willenheimer R, Van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III. Circulation. 2005;112(16):2426–2435.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–1552.
   PubMed Web of Science ®Google Scholar
• Carson P1, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-heart failure trial study group. J Card Fail. 1999;5(3):178–187.
   PubMedGoogle Scholar
• Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344(18):1351–1357.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057.
   PubMed Web of Science ®Google Scholar
• Ziaeian B, Fonarow GC, Heidenreich PA. Clinical effectiveness of hydralazine-isosorbide dinitrate in African-American patients with heart failure. JACC Heart Fail. 2017 Sep;5(9):632–639.
   PubMed Web of Science ®Google Scholar
• Cole RT, Kalogeropoulos AP, Georgiopoulou VV, et al. Hydralazine and isosorbide dinitrate in heart failure -historical perspective, mechanisms, and future directions. Circulation. 2011;123:2414–2422.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Fonarow GC, Albert NM, et al. Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol. 2010;105(2):255–260.
   PubMed Web of Science ®Google Scholar
• Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol Off J Ger Card Soc. 2013;102(1):11–22.
   PubMed Web of Science ®Google Scholar
• Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet Lond Engl. 2010;376(9744):886–894.
   PubMed Web of Science ®Google Scholar
• Böhm M, Perez A-C, Jhund PS, et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014;16(7):778–787.
   PubMed Web of Science ®Google Scholar
• Castagno D, Skali H, Takeuchi M, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in heart failure: assessment of reduction in mortality and morbidity) program. J Am Coll Cardiol. 2012;59(20):1785–1795.
   PubMedGoogle Scholar
• Maeder MT, Kaye DM. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. Int J Cardiol. 2012;155(2):249–256.
   PubMed Web of Science ®Google Scholar
• Shang X, Lu R, Liu M, et al. Heart rate and outcomes in patients with heart failure with preserved ejection fraction. Medicine (Baltimore). 2017;96:43.
   Google Scholar
• Shaaya G, Al-Khazaali A, Arora R. Heart rate as a biomarker in heart failure: role of heart rate lowering agents. Am J Ther. 2017;24(5):e532–e539.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;79(12):1645–1650.
   PubMed Web of Science ®Google Scholar
• Böhm M, Robertson M, Borer J, et al. Effect of visit‐to‐visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the i f inhibitor ivabradine trial (SHIFT) trial. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2016;5:2.
   Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet Lond Engl. 2010;376(9744):875–885. .
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15(11):1296–1303.
   PubMed Web of Science ®Google Scholar
• Voors AA, Van Veldhuisen DJ, Robertson M, et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur J Heart Fail. 2014;16(4):426–434.
   PubMed Web of Science ®Google Scholar
• Böhm M, Komajda M, Borer JS, et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail. 2017 Oct. DOI:10.1002/ejhf.1021
   Web of Science ®Google Scholar
• Komajda M, Tavazzi L, Francq BG, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail. 2015;17(12):1294–1301.
   PubMed Web of Science ®Google Scholar
• Borer JS, Böhm M, Ford I, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol. 2014;113(3):497–503.
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer JS, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail. 2014;16(7):810–816.
   PubMed Web of Science ®Google Scholar
• Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263–2270.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol. 2013;170(2):182–188.
   PubMed Web of Science ®Google Scholar
• Komajda M, Tavazzi L, Swedberg K, et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur J Heart Fail. 2016;18(9):1182–1189.
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine’s effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15(1):79–84.
   PubMed Web of Science ®Google Scholar
• Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33(22):2813–2820.
   PubMed Web of Science ®Google Scholar
• Rohm I, Kretzschmar D, Pistulli R, et al. Impact of ivabradine on inflammatory markers in chronic heart failure. J Immunol Res. 2016;2016:6949320.
   PubMedGoogle Scholar
• Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19(11):1495–1503.
   PubMed Web of Science ®Google Scholar
• Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31(9):961–974.
   PubMed Web of Science ®Google Scholar
• Martin RIR, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014 Jun;heartjnl-2014–305482. DOI:10.1136/heartjnl-2014-305482
   Google Scholar
• Majewski S, Slomka S, Zielinska-Wyderkiewicz E, et al. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study. Am J Cardiovasc Drugs Drugs Devices Interv. 2012;12(3):179–188.
   PubMed Web of Science ®Google Scholar
• Zugck C, Störk S, Stöckl G, RELIf-CHF study investigators. Long-term treatment with ivabradine over 12months in patients with chronic heart failure in clinical practice: effect on symptoms, quality of life and hospitalizations. Int J Cardiol. 2017;240:258–264. .
   PubMed Web of Science ®Google Scholar
• Kansal AR, Cowie MR, Kielhorn A, et al. Cost-effectiveness of ivabradine for heart failure in the united states. J Am Heart Assoc. 2016;5:5.
   Web of Science ®Google Scholar
• Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119(18):2516–2525.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Aronow WS, Mondal P, et al. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci AMS. 2017;13(5):1207–1216.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–111.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. .
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Aronow WS, Mondal P, et al. Limitations of sacubitril/valsartan in the management of heart failure. Am J Ther. 2017;24(2):e234–e239.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Andries G, Biswas M, et al. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vasc Health Risk Manag. 2017;13:369–382.
   PubMed Web of Science ®Google Scholar
• Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy. Circ Heart Fail. 2016;9:9.
   Web of Science ®Google Scholar
• McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2014 Nov ehu455. DOI:10.1093/eurheartj/ehu455
   Google Scholar
• Packer M, McMurray JJV, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Kachadourian J, et al. Abstract 17948: reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the paradigm-HF study. Circulation. 2016;134(Suppl 1):A17948–A17948.
   Google Scholar
• McMurray JJV, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart Br Card Soc. 2017 Dec. DOI:10.1136/heartjnl-2016-310661
   Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387–1395.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction - full text view. ClinicalTrials.gov. [cited 2018 Feb 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01920711.
   Google Scholar
• Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017;2(1):79–85.
   PubMed Web of Science ®Google Scholar
• Norberg H, Bergdahl E, Lindmark K. Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail. Jan 2018. DOI:10.1002/ehf2.12251
   PubMed Web of Science ®Google Scholar
• Aronow WS, Shamliyan TA. Benefits and harms of sacubitril in adults with heart failure and reduced left ventricular ejection fraction. Am J Cardiol. 2017;120(7):1166–1170. .
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N. Sacubitril/valsartan in clinical practice: the Italian experience. Cardiology. 2017;138(Suppl. 1):1–2.
   PubMedGoogle Scholar
• De Vecchis R, Ariano C, Di Biase G, et al. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction: a retrospective cohort study. Herz. Jan 2018. DOI:10.1007/s00059-017-4671-1
   Web of Science ®Google Scholar
• Cannon JA, Shen L, Jhund PS, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129–137.
   PubMed Web of Science ®Google Scholar